To assess the impact of routine thoracentesis on diagnostic assessment and therapeutic measures in patients with clinically documented pleural effusions. Design and setting: Prospective, 1-year, three-center study in medical ICU (MICU) patients with physical and radiographic evidence of pleural effusion. Patients: Of 1,351 patients admitted to three MICUs during the study period, 113 patients had physical and radiographic evidence of pleural effusion, yielding an annual incidence of 8.4%. Intervention: Routine thoracentesis in 82 patients without contraindications to thoracentesis. Measurements and results: Twenty patients (24.4%) had a transudate, 35 patients (42.7%) had an infectious exudate (parapneumonic, n ‫؍‬ 21; empyema, n ‫؍‬ 14), and 27 patients (32.9%) had a noninfectious exudate. Laboratory parameters including the leukocyte count, the neutrophil percentage in pleural fluid, and the fluid/serum protein and lactate dehydrogenase ratios differed significantly among the three groups. Thoracentesis yielded improvements in the diagnosis and/or treatment in 46 patients (56%): the presumptive (prethoracentesis) diagnosis was changed in 37 patients (32 patients with certain benefit and 5 patients with probable benefit from thoracentesis), of whom 27 patients received a change in treatment based on the new diagnosis; 9 other patients received a change in treatment although the diagnosis remained the same. The only complications were pneumothorax in six patients (7%), all with a favorable outcome after drainage. Conclusion: Infection was the main cause of pleural effusions detected based on physical and radiographic findings in our MICU population. Routine thoracentesis proved a simple and safe means of improving the diagnosis and treatment.
R
easons for medical ICU (MICU) admission are often related to parenchymal lung disorders with or without abnormalities of other organs. Pleural effusions in MICU patients are rarely a manifestation of primary pleural disease: most reflect a pulmonary or extrapulmonary disorder. Both fluid overload and pleural effusions are common in MICU patients, suggesting a link between the two. However, few studies have evaluated the incidence and etiologies of pleural effusions in MICU patients. Mattison et al 1 reported a predominance of transudates in 62 consecutive MICU patients with pleural effusions detected using chest ultrasonography, including 14 patients investigated by thoracentesis.
When a pleural effusion is detected, the need for and safety of thoracentesis must be evaluated; if the fluid is an exudate, a cause must be sought. 2 Pleural effusions of Ͻ 500 mL may produce no more than a subtle haziness over the lower lungs on chest radiographs obtained in the supine or semirecumbent position, as is often the case in MICU patients. 3, 4 Although chest ultrasound and CT have been proved effective in detecting small pleural effusions, 1, 5 the clinical relevance of these small effusions in MICU patients remains unclear. Patients with physical and radiographic evidence of pleural effusion may be more likely to benefit from thoracentesis than patients with a pleural effusion detectable only by ultrasound and/or CT. In a prospective, three-center study of MICU patients with physical and radiographic evidence of pleural effusion, we performed routine thoracentesis to evaluate the contribution of this procedure to the etiologic diagnosis and treatment.
Materials and Methods
All consecutive patients admitted to three teaching hospital MICUs (37 beds in all) from November 1, 1997, to November 1, 1998, were screened prospectively for physical and radiographic evidence of pleural effusion.
The following data were collected: (1) age and sex, comorbidities, reasons for MICU admission, simplified acute physiology (SAPS) II score 6 at MICU admission, and vital signs and clinical data on the day of thoracentesis (temperature, ankle edema, cardiogenic pulmonary edema, need for mechanical ventilation, and need for vasopressors); (2) characteristics of the effusion: side, unilateral or bilateral, time from MICU admission to thoracentesis, appearance, and laboratory findings (protein, albumin, glucose, and lactate dehydrogenase [LDH] levels; leukocyte count and proportion of neutrophils; and smear and culture findings for bacteria and mycobacteria); and (3) serum test results on the day of thoracentesis (protein, albumin, LDH, and leukocyte count).
Pleural effusion was diagnosed based on physical examination whenever possible: absent breath sounds at auscultation, flatness to percussion, and reduced tactile fremitus in patients able to speak. Confirmation of the effusion was sought routinely on a chest radiograph obtained in the supine or semirecumbent position and reviewed independently by three clinicians (two senior and one junior). The size and side of the effusion were noted. Blunting of the costophrenic angle or obscuring of the lower lung defined a small effusion, opacification of the lower and middle lung defined a moderate effusion, and opacification of the entire lung defined a large effusion. When a pleural effusion was detected, thoracentesis was performed in accordance with published guidelines. 7 Contraindications to thoracentesis included hemodynamic instability, severe respiratory insufficiency (Pao 2 Ͻ 50 mm Hg on room air), a small effusion, and severe hemostasis alterations (platelets Ͻ 50 G/L, fibrinogen Ͻ 2 g/L, prothrombin Ͻ 50% of control, or cephalin-activated time more than twice the control).
Clinically documented pneumonia was defined by association of fever, hypoxemia, and pulmonary infiltrate at chest radiography. In all these patients, an invasive (fibroscopy with distal protected specimen) or noninvasive (sputum or tracheal aspiration analysis) microbiological diagnosis of pneumonia was performed.
The cause of pleural effusion was determined based on the physical and radiographic findings (presumptive diagnosis) and on the results of thoracentesis if performed (definitive diagnosis 11 ; malignancy (cytologic specimen finding positive for malignant cells) 12 ; hemothorax (blood at thoracentesis); and postoperative effusion (effusion occurring after abdominal surgery). 13 Pancreatic effusions were defined as pleural effusions associated with clinically and biologically documented pancreatitis with compatible CT findings. Pulmonary emboli were all diagnosed using helicoidal CT. Treatment changes attributed to the results of thoracentesis were recorded; they consisted of introduction of diuretics or vasopressors, adjustment of antibiotics according to microbiological findings, albumin therapy, antitumoral chemotherapy, steroids, and chest tube drainage. In bilateral effusions, only one side was tapped for the purpose of this study. Complications of thoracentesis were also recorded.
Statistical Analysis
Results are reported as medians (quartiles). Comparisons between groups used the 2 test for categorical variables (or Fisher's Exact Test when appropriate) and the nonparametric Wilcoxon test for continuous variables (or the Kruskal-Wallis test when appropriate). The usefulness of thoracentesis was evaluated separately for the diagnosis and the treatment. Diagnostic usefulness was defined as a change in the presumptive diagnosis made by two senior physicians and one junior physician, and therapeutic usefulness as a change in treatment. Three situations were identified: (1) certain and (2) probable benefit of thoracentesis regarding diagnosis assessment, and (3) certain benefit of thoracentesis regarding change in treatment. In the first and third situations, thoracentesis directly allowed physicians to perform a new diagnosis or to begin a new treatment; in the second situation, results of thoracentesis invalidated the presumptive diagnosis and helped physicians to reconsider their diagnosis and to identify the accurate etiology of the pleural effusion. Intraobserver agreement before and after thoracentesis was assessed using the test to compare the same group of observers before and after thoracentesis; a coefficient Ͻ 0.50 was taken to indicate poor agreement.
Results
Of the 1,351 patients admitted to the three MICU departments during the 1-year study period, 113 patients had physical and radiographic evidence of pleural effusion, yielding an annual incidence of 8.4%.
Patient Characteristics
There were 59 male and 54 female patients (mean age, 59 years; range, 42 to 68 years; Table 1 ). Eight patients (7%) were neutropenic, 8 patients (7%) had cirrhosis, 17 patients (15%) had documented heart failure, and 35 patients (31%) had hypertension. Respiratory failure was the most common reason for MICU admission; 68 patients (60%) were receiving mechanical ventilation at the time of thoracentesis, and 47 patients (42%) required a positive endexpiratory pressure (PEEP) Ն 5 cm H 2 O; median Pao 2 /fraction of inspired oxygen was 186 (quartile range, 94 to 245), and 44 patients (53.7%) had Pao 2 /fraction of inspired oxygen Ͻ 200. Pleural effusion was detected at MICU admission in 83 patients (74%) and Ͼ 5 days after MICU admission in 30 patients (26%). Based on radiographic findings, the effusion was small in 7 patients (6.2%), moderate in 81 patients (71.7%), and large in 25 patients (22.1%).
Patients With a Contraindication to Thoracentesis
Thoracentesis was not performed in 27 patients because of hemodynamic instability (n ϭ 6), severe respiratory failure (n ϭ 6), severe hemostasis alterations (n ϭ 8), or a pleural effusion considered too small to be safely tapped (n ϭ 7). There were no significant differences in terms of age, comorbidities, reasons for MICU admission, severity scores at MICU admission, clinical characteristics, presumptive etiologic diagnosis, or mortality rate between patients who did and did not undergo thoracentesis.
Patients Without Contraindications to Thoracentesis
The mean time from MICU admission to thoracentesis was 2 days (0 to 6 days). Of the 86 patients who underwent thoracentesis, 4 patients had a dry tap. Fluid was obtained in 82 patients (73%). The fluid was clear in 39 patients (48%), blood-tinged in 28 patients (35%), hemorrhagic in 5 patients (6%), cloudy in 5 patients (6%), and turbid in 5 patients (6%). The effusion was a transudate in 20 patients (24.4%), a noninfectious exudate in 27 patients (32.9%), and an infectious exudate in 35 patients (42.7%). Most transudates (16 of 20 transudates) were attributable mainly to fluid overload associated with congestive heart failure; the cause was hypoalbuminemia in four patients, including two patients with liver failure. Of the 35 patients with infectious effusions, 21 patients had a parapneumonic effusion and 14 patients had empyema. Causes of the noninfectious exudates were malignancy (n ϭ 10), pulmonary embolism (n ϭ 4), postoperative effusion (n ϭ 4); hemothorax (n ϭ 4), and pancreatitis (n ϭ 2); in three patients, no cause was found. Microorganisms associated with empyema were Staphylococcus aureus (n ϭ 3), Streptococcus spp (n ϭ 3), Escherichia coli (n ϭ 2), Klebsiella pneumoniae (n ϭ 2), Mycobacterium tuberculosis (n ϭ 2), and Peptostreptococcus (n ϭ 2). In all the 45 patients with clinically documented pneumonia (fever, hypoxemia, and pulmonary infiltrate at chest radiography) an invasive (distal protected) or noninvasive (sputum or tracheal aspiration analysis) microbiological diagnosis of pneumonia was performed. The results were positive in 25 patients, including 13 patients with parapneumonic pleural effusion. Microorganisms involved were Pseudomonas aeruginosa (n ϭ 4), S aureus (n ϭ 3), Streptococcus spp (n ϭ 3), Streptococcus pneumoniae (n ϭ 2), and Proteus mirabilis (n ϭ 1). 
Comparison of Patients Based on the Cause of Pleural Effusion
Patient characteristics according to thoracentesis findings are detailed in Table 2 . Clinical features at MICU admission differed significantly between patients with and without a transudate. In patients with a transudate, MICU admission for cardiogenic pulmonary edema, bilateral ankle edema at presentation, and documented heart failure were more common than in the patients with infectious or noninfectious exudates. Two clinical features, namely, fever at MICU admission and a unilateral effusion, were more common in patients with infectious exudates than in transudates, but failed to distinguish between infectious and noninfectious exudates. Eight of the 19 patients admitted to the MICU for cardiogenic pulmonary edema had an exudate, as did 23 of the 40 patients with ankle edema and 4 of the 13 patients with documented heart failure. These 35 exudates in patients with pulmonary edema, pedal edema, or documented heart failure included parapneumonic effusions (n ϭ 15), empyema (n ϭ 2), hemothorax (n ϭ 3), positional atelectasis (n ϭ 3), postoperative effusions (n ϭ 3), pancreatitis (n ϭ 2), metastatic effusions (n ϭ 4), pulmonary embolism (n ϭ 1), and exudates from unknown origin (n ϭ 2). Moreover, six patients with cardiogenic pulmonary edema had a unilateral effusion, including parapneumonic effusion (n ϭ 1), empyema (n ϭ 1), and pulmonary embolism (n ϭ 1). Although patients with transudates had a higher mean SAPS II score at MICU admission, they had no significant differences in mortality or ICU length of stay as compared with the two other groups. No significant differences were found among the three pleural effusion groups for age, immunologic status, blood leukocytosis, presence of nonpleural infection, or need for vasopressors or mechanical ventilation at the time of thoracentesis.
Usefulness of Thoracentesis
Overall, thoracentesis was useful in 46 patients (56%; Table 3 ). The thoracentesis-based (definite) diagnosis was different from the presumptive diagnosis in 37 patients (45.1%), including 32 patients with certain benefit from thoracentesis and 5 patients in whom thoracentesis invalidated the presumptive diagnosis without assessing the definitive diagnosis. Of the 37 patients in whom thoracentesis was useful regarding diagnosis assessment, 27 patients received a change in treatment based on thoracentesis findings (Table 3) ; the coefficient for intraobserver agreement was 0.41 (0.16 to 0.84), indicating a marked improvement in the etiologic diagnosis of pleural effusion after thoracentesis. Nine patients (11%) received a change in treatment directly attributable to thoracentesis although their diagnosis remained unchanged: six patients with empyema were switched to more active antibiotics based on microbiological pleural fluid studies, two patients with hypoalbuminemia-related transudates received albumin, and one patient with pleural cancer received antitumoral chemotherapy based on cytologic pleural fluid results. On the day of thoracentesis, none of the study parameters predicted whether 
Complications of Thoracentesis
Pneumothoraces occurred in six patients (7%), including five patients receiving mechanical ventilation with a PEEP Ն 5 cm H 2 O; all of them resolved satisfactorily after bedside drainage. No cases of thoracentesis-related hemothorax or pleural infection were seen.
Discussion
A pleural effusion in an MICU patient is frequently overshadowed by the parenchymal lung disorder or other organ dysfunction that causes it. Few patients come to the MICU because of a pleural condition such as hemothorax, spontaneous pneumothorax, or a large pleural effusion.
Although thoracentesis has been reported to be safe, even in patients receiving mechanical ventilation, 14 -16 few studies have focused on its feasibility and clinical implications in MICU patients. The prospective, three-center, 1-year study reported here was designed to evaluate the usefulness of routine thoracentesis in consecutive MICU patients with physical and radiographic evidence of pleural effusion. Thoracentesis resulted in a change in diagnosis and/or treatment in as many as 46 of the 82 patients without of contraindications to the procedure.
Patients who benefited from thoracentesis presented similar outcomes than those with contraindications to thoracentesis or those who did not benefit from thoracentesis. Nevertheless, we believe that mortality could not represent a relevant variable of interest in our study. Indeed, improvement in diagnostic and therapeutic strategies may have other advantages such as better quality of care. Moreover, patients who benefited from thoracentesis had trends toward a shorter ICU stay.
The incidence of pleural effusion during the 1-year study period in the patients of the three MICUs was 8.4%. This relatively low figure may be an underestimation, since effusions were diagnosed based on physical and radiographic data, which can miss small amounts of fluid. Moreover, clinical diagnosis of pleural effusions could be impaired in some ICU patients in whom auscultation and percussion of the chest may be difficult. Other diagnostic tools such as ultrasound or CT can detect small effusions, but the clinical significance of these remains unclear. 1, 5 Nevertheless, there are no data to suggest that small effusions detected by ultrasounds are qualitatively different from those detected clinically (examination plus radiograph). Therefore, our findings may be applied to patients with small effusions.
In our patients, infection was the most common cause of pleural effusion, with 43% of cases (35 of 82 patients). Three fifths of the infectious effusions were related to pneumonia, and the remainder were empyemas. These results are at variance with previous reports that transudates dominate in MICU patients. 1 For instance, Mattison et al 1 found a 62% prevalence of heart failure-related transudates in a study of 62 patients, of whom only 14 patients underwent thoracentesis; however, some of the untapped effusions in their study may have been uncomplicated parapneumonic effusions or other types of exudates. Moreover, published guidelines 2 do not recommend thoracentesis in patients known to have left-heart dysfunction associated with pleural effusion unless the effusion is febrile and/or unilateral and/or associated with chest pain. In MICU patients, this restriction of thoracentesis use in patients with known heart failure may result in overestimation of transudates related to heart failure and, consequently, in misdiagnosis of effusions due to other causes.
Diagnosing infectious effusions is important to improve the treatment and prognosis. In our study, routine thoracentesis provided the correct diagnosis in eight cases of pleural empyema for which the presumptive cause was a parapneumonic effusion (n ϭ 4), pulmonary embolism (n ϭ 1), hemothorax (n ϭ 2), or surgery (n ϭ 1). This shows that commonly used parameters, including body temperature and leukocytosis, may fail to indicate empyema, leaving routine thoracentesis as the best diagnostic tool.
Noninfectious exudates were common in our study. Their causes were diverse, with a noticeable proportion of pleural cancers. Here again, thoracentesis can improve the treatment and prognosis, particularly at discharge from the MICU.
To the best of our knowledge, our study is the first to evaluate the diagnostic and therapeutic usefulness of routine thoracentesis in critically ill patients with pleural effusions. Thoracentesis improved the diagnosis and treatment, although the reductions in length of stay and mortality were nonsignificant as compared with the patients who had no benefit from thoracentesis. As previously reported in ICU patients, routine thoracentesis was safe. 14 -16 Given that more than one half our patients underwent thoracentesis and that neither clinical nor laboratory parameters predicted the usefulness of this proce-dure, we suggest that thoracentesis should be performed routinely in ICU patients with a pleural effusion, above all in patients recently admitted to the ICU. If our findings are confirmed in larger studies, this safe and cheap procedure may provide large gains in diagnosis, treatment, and even prognosis.
